Galderma: H1 Beat and raise; Expect 1% upside to FY26 cons core EBITDA

Research evidence excerpt

Galderma: H1 Beat and raise; Expect 1% upside to FY26 cons core EBITDA

Marjan Daeipour - Specialist Sales - European Healthcare AC (44 20) 7134-1329 Europe Specialist Sales J P M O R G A N

marjan.daeipour@jpmorgan.com JPM | Galderma: H1 Beat and raise;

J.P. Morgan Securities plc Expect 1% upside to FY26 cons

core EBITDA

23 July 2026

Managed Care, Facilities, Distribution, Technology & PBMs:

Lisa Gill lisa.c.gill@jpmorgan.com+1 212 622 6466

John Stansel John.Stansel@jpmorgan.com+1212 622 0083

Benjamin Rossi Benjamin.Rossi@jpmorgan.com+1 212 622 9603

Alex Comer (CEEMEA) Alex.r.comer@jpmorgan.com+44 207 134 5945

Disclaimers:

This communication is intended for institutional and selected professional clients of J.P. Morgan only. Do not forward outside of your own organization.

You are receiving this email because you are a client of J.P. Morgan. If you would like to stop receiving the Healthcare Sector Specialist Commentary please email Marjan Daeipour at

marjan.daeipour@jpmorgan.com.

This material has been prepared by personnel in the Sales & Trading Department and may include non-independent research (investment recommendations) which, for the purposes of MiFID 2

compliance, may also constitute a marketing communication. As such, this material has not been prepared in accordance with legal requirements designed to promote the independence of Investment

Research, including but not limited to the prohibition on dealing ahead of the dissemination of Investment Research. It is not a product of J.P. Morgan’s Research Department. It is not a research report,

investment research or independent research and is not intended as such. This material is subject to the disclosures available at the following site http://www.jpmorgan.com/pages/disclosures/